Won Jin Ho

Medicine & Life Sciences

1. Tumor Microenvironment 100%
2. Neoplasms 80%
3. Hepatocellular Carcinoma 61%
4. Immunotherapy 56%
5. Adenocarcinoma 51%
6. Nivolumab 43%
7. Pancreatic Neoplasms 41%
8. cabozantinib 41%
9. T-Lymphocytes 35%
10. pembrolizumab 32%
11. Immunity 30%
12. Immunologic Monitoring 28%
13. Micronutrients 24%
14. Allergy and Immunology 24%
15. Squamous Cell Carcinoma of Head and Neck 24%
16. Therapeutics 22%
17. Biomarkers 22%
18. B-Lymphocytes 22%
19. Ipilimumab 22%
20. Renal Cell Carcinoma 20%
21. Lymph Nodes 20%
22. Stomach Neoplasms 18%
23. Neoadjuvant Therapy 18%
24. Spatial Analysis 18%
25. Clinical Trials 18%
26. 15-hydroxyprostaglandin dehydrogenase 18%
27. Stomach 16%
28. Ligands 16%
29. Granzymes 16%
30. Survival 16%
31. B-Cell Activating Factor 15%
32. Cellular Spheroids 15%
33. Signet Ring Cell Carcinoma 15%
34. Macrophages 15%
35. Drug Resistance 14%
36. Chimeric Antigen Receptors 14%
37. Single-Cell Analysis 14%
38. Fibroblast Growth Factor 2 14%
39. Immunohistochemistry 14%
40. Interleukin-15 13%
41. Squamous Cell Neoplasms 13%
42. Protein Tyrosine Phosphatases 13%
43. Microsatellite Instability 13%
44. Liver 13%
45. Apoptosis 13%
46. Cancer Vaccines 13%
47. Head and Neck Neoplasms 13%
48. DNA Mismatch Repair 12%
49. Preclinical Drug Evaluations 12%
50. Natural Killer Cells 12%